阻塞(统计)
抗体
癌症研究
材料科学
生物医学工程
生物
免疫学
医学
计算机科学
计算机网络
作者
Huu Tuan Nguyen,Ellen L. Kan,Mouhita Humayun,Nadia Gurvich,Giovanni S. Offeddu,Zhengpeng Wan,Mark F. Coughlin,Diana C. Renteria,Andreas Loew,Susan Wilson,Christie Zhang,Vivian Vu,Sharon Wei Ling Lee,Seng-Lai Tan,David A. Barbie,Jonathan Hsu,Mark R. Gillrie,Roger D. Kamm
出处
期刊:Biomaterials
[Elsevier BV]
日期:2024-07-29
卷期号:312: 122731-122731
被引量:25
标识
DOI:10.1016/j.biomaterials.2024.122731
摘要
Tumor-associated inflammation drives cancer progression and therapy resistance, often linked to the infiltration of monocyte-derived tumor-associated macrophages (TAMs), which are associated with poor prognosis in various cancers. To advance immunotherapies, testing on immunocompetent pre-clinical models of human tissue is crucial. We have developed an in vitro model of microvascular networks with tumor spheroids or patient tissues to assess monocyte trafficking into tumors and evaluate immunotherapies targeting the human tumor microenvironment. Our findings demonstrate that macrophages in vascularized breast and lung tumor models can enhance monocyte recruitment via CCL7 and CCL2, mediated by CSF-1R. Additionally, a multispecific antibody targeting CSF-1R, CCR2, and neutralizing TGF-β (CSF1R/CCR2/TGF-β Ab) repolarizes TAMs towards an anti-tumoral M1-like phenotype, reduces monocyte chemoattractant protein secretion, and blocks monocyte migration. This antibody also inhibits monocyte recruitment in patient-specific vascularized tumor models. In summary, this vascularized tumor model recapitulates the monocyte recruitment cascade, enabling functional testing of innovative therapeutic antibodies targeting TAMs in the tumor microenvironment.
科研通智能强力驱动
Strongly Powered by AbleSci AI